Avastin Compounding Does Not Increase Endophthalmitis Risk, Study Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Observational cohort data suggest infection risk is lower with off-label use of compounded Avastin than with Genentech's approved ophthalmic treatment, Lucentis, although not statistically significant.
You may also be interested in...
Avastin Safety Questions In Wet AMD Linger With Two-Year CATT Results
Over two years, serious adverse events occurred at a 40% rate for patients treated with Avastin and at a 32% rate for patients receiving Lucentis, CATT researchers report in an article published in the journal Ophthalmology.
Lucentis And Avastin Stack Up In CATT, Forcing Genentech/Novartis To Play Defense
The efficacy of low-cost Avastin and pricier Lucentis for the treatment of wet-AMD are similar in the first head-to-head clinical trial to compare the two drugs, though Novartis and Genentech call out safety uncertainties.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.